- Home
- ZENV vs MGNX Comparison
ZENV vs MGNX Comparison
Compare ZENV & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- MGNX
- Stock Information
- Founded
- ZENV 2005
- MGNX 2000
- Country
- ZENV Brazil
- MGNX United States
- Employees
- ZENV N/A
- MGNX N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- MGNX Health Care
- Exchange
- ZENV Nasdaq
- MGNX Nasdaq
- Market Cap
- ZENV 79.2M
- MGNX 87.7M
- IPO Year
- ZENV 2021
- MGNX 2013
- Fundamental
- Price
- ZENV $1.46
- MGNX $1.58
- Analyst Decision
- ZENV
- MGNX Hold
- Analyst Count
- ZENV 0
- MGNX 9
- Target Price
- ZENV N/A
- MGNX $5.33
- AVG Volume (30 Days)
- ZENV 78.9K
- MGNX 1.2M
- Earning Date
- ZENV 09-04-2025
- MGNX 08-05-2025
- Dividend Yield
- ZENV N/A
- MGNX N/A
- EPS Growth
- ZENV N/A
- MGNX N/A
- EPS
- ZENV N/A
- MGNX N/A
- Revenue
- ZENV $181,911,572.00
- MGNX $154,050,000.00
- Revenue This Year
- ZENV $8.58
- MGNX N/A
- Revenue Next Year
- ZENV $8.83
- MGNX N/A
- P/E Ratio
- ZENV N/A
- MGNX N/A
- Revenue Growth
- ZENV 23.99
- MGNX 255.31
- 52 Week Low
- ZENV $1.02
- MGNX $0.99
- 52 Week High
- ZENV $3.03
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- ZENV 46.93
- MGNX 59.02
- Support Level
- ZENV $1.40
- MGNX $1.34
- Resistance Level
- ZENV $1.50
- MGNX $1.65
- Average True Range (ATR)
- ZENV 0.09
- MGNX 0.11
- MACD
- ZENV -0.01
- MGNX 0.04
- Stochastic Oscillator
- ZENV 36.36
- MGNX 91.40
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.